Handelsavisen
prelaunch
12
1264.TWO TPEx Food Retail & Distribution

1264.Two

$271,50
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
10,1B TWD
P/E
EV / Rev
Div yield
5,30 %
Op margin
16,8 %
ROE
20,7 %
Net margin
11,2 %
Debt / equity
0,18
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

1264.TWO operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

Business. 1264.TWO operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryFood Retail & Distribution
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
20,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1264.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1264.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    1264.TWO operates in the Food & Drug Retailing industry, generating revenue primarily through the sale of food and drug products to consumers.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryFood Retail & Distribution
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    1264.TWO maintains a strong liquidity position with a current ratio of 2.51, indicating the company can cover its short-term liabilities more than twice over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 2.74 suggests the market values the company at a premium to its book value, while the price-to-earnings ratio of 13.24 indicates a moderate valuation relative to earnings.

    The company's profitability is robust, with a return on equity of 20.66% and a return on assets of 12.79%, both exceeding the typical thresholds for the Food Retail & Distribution industry. The operating margin, calculated as operating income of 1137.2 million TWD on revenue of 6.78 billion TWD, reflects a healthy margin of 16.8%, which is in line with industry expectations. The gross margin of 32.2% further supports the company's ability to maintain pricing power and control costs.

    Geographically, 1264.TWO's revenue is concentrated in its domestic market, with no disclosed international segments. The company's business is not segmented by product lines in the latest financial data, but its primary activity is the retailing of food and drug products. This concentration may expose the company to regional economic fluctuations and regulatory changes.

    Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The operating cash flow of 1.04 billion TWD and free cash flow of 169.6 million TWD support the company's ability to fund operations and reinvest in the business. The capital expenditure of -259.1 million TWD indicates a reduction in investment in physical assets, which may signal a shift in strategic focus or a response to market conditions.

    The risk assessment for 1264.TWO highlights a medium liquidity risk due to the negative net cash position after debt. The dilution risk is low, with no significant dilution expected in the near term. The company's debt-to-equity ratio of 0.18 suggests a conservative capital structure, with limited leverage. However, the company's reliance on domestic markets and the absence of international diversification may increase its exposure to local economic and regulatory risks.

    Recent filings and transcripts do not indicate any material events or strategic shifts for 1264.TWO. The company's financial performance and operational strategy appear to be stable, with no significant changes in management or business direction reported in the latest disclosures.

    Key takeaways
    • 1264.TWO has a strong liquidity position with a current ratio of 2.51, but its net cash is negative after subtracting total debt.
    • The company's profitability is robust, with a return on equity of 20.66% and a return on assets of 12.79%.
    • 1264.TWO's revenue is concentrated in its domestic market, with no disclosed international segments.
    • The company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year.
    • The risk assessment highlights a medium liquidity risk and a low dilution risk, with a conservative capital structure indicated by a debt-to-equity ratio of 0.18.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $271,50
    Market cap
    $10.04B
    Enterprise value
    $10.56B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    10.2x
    P / B
    2.7x
    P / Tangible book
    2.7x
    Tangible book
    $3.67B
    Net cash
    -$514.2M
    Current ratio
    2.5
    Debt / equity
    0.2
    ROA
    12.8%
    ROE
    20.7%
    Cash conversion
    137.0%
    CapEx / revenue
    -3.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin16,8 %Best in class
    Net Margin11,2 %Best in class
    ROE20,7 %Best in class
    Capex / Rev-3,8 %Bottom quartile
    D/E0,18Above median
    Cash Conv1,37Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 1264.TWO Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1264.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage